FDA Approves Sanofi Inc.'s Dengue Vaccine
02 Maggio 2019 - 1:38AM
Dow Jones News
By Maria Armental
Sanofi's dengue vaccine was approved in the U.S., the first
vaccine cleared to treat the mosquito-borne virus in the country
and U.S. territories like Puerto Rico, U.S. Virgin Islands,
American Samoa and Guam.
The vaccine, Dengvaxia, was approved by the Food and Drug
Administration to treat those aged 9 through 16, against the
mosquito-borne virus.
The disease is complex to vaccinate against because it can be
caused by four different strains of the same virus. Dengvaxia,
first approved in Mexico in 2015, targets the four strains; but
health regulators warn that it should only be given to those who
have previously had a dengue infection, and live in areas where
dengue is endemic.
Those who haven't had a previous dengue infection face a higher
risk of contracting severe dengue when vaccinated with
Dengvaxia.
It is unknown whether Dengvaxia is safe or protective for people
living in areas where dengue isn't endemic or who travel to dengue
endemic areas, the FDA said.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
May 01, 2019 19:23 ET (23:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Apr 2023 a Apr 2024